In last trading session, Esperion Therapeutics Inc (NASDAQ:ESPR) saw 4.92 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $0.95 trading at $0.02 or 2.10% at ring of the bell on the day assigns it a market valuation of $188.08M. That closing price of ESPR’s stock is at a discount of -314.74% from its 52-week high price of $3.94 and is indicating a premium of 13.68% from its 52-week low price of $0.82. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.84 million shares which gives us an average trading volume of 4.52 million if we extend that period to 3-months.

For Esperion Therapeutics Inc (ESPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.78. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.

Esperion Therapeutics Inc (NASDAQ:ESPR) trade information

Upright in the green during last session for gaining 2.10%, in the last five days ESPR remained trading in the red while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $0.95 price level, adding 10.38% to its value on the day. Esperion Therapeutics Inc’s shares saw a change of -56.85% in year-to-date performance and have moved -4.67% in past 5-day. Esperion Therapeutics Inc (NASDAQ:ESPR) showed a performance of -45.45% in past 30-days. Number of shares sold short was 28.02 million shares which calculate 6.23 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 88.12% to its current value. Analysts have been projecting 8 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -742.11% in reaching the projected high whereas dropping to the targeted low would mean a loss of -742.11% for stock’s current value.

Esperion Therapeutics Inc (ESPR) estimates and forecasts

This year revenue growth is estimated to rise 2.59% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 53.83M for the same. And 7 analysts are in estimates of company making revenue of 60.74M in the next quarter. Company posted 137.74M and 73.83M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 40.11% during past 5 years.

Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders

Insiders are in possession of 0.51% of company’s total shares while institution are holding 58.76 percent of that, with stock having share float percentage of 59.06%. Investors also watch the number of corporate investors in a company very closely, which is 58.76% institutions for Esperion Therapeutics Inc that are currently holding shares of the company. WASATCH ADVISORS LP is the top institutional holder at ESPR for having 16.86 million shares of worth $37.44 million. And as of 2024-06-30, it was holding 8.9319 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 13.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4068 of outstanding shares, having a total worth of $31.04 million.

On the other hand, WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 6.68 shares of worth $6.34 million or 3.37% of the total outstanding shares. The later fund manager was in possession of 6.18 shares on Dec 31, 2024 , making its stake of worth around $5.87 million in the company or a holder of 3.12% of company’s stock.